Sanofi and Skyhawk Therapeutics announced an exclusive worldwide collaboration to discover and develop novel small molecule RNA-splicing modulators for challenging oncology and immunology targets. Sanofi paid $54M upfront with potentially over $2B in aggregate development, regulatory and commercial milestones plus royalties.
Key facts
AnnouncedJul 19, 2022
ClosedJul 19, 2022
Deal value$2.1B
Deal typeCo-Development
Therapeutic areaOncology and immunology
IndicationsOncology and immunology
Key assetsRNA splicing modulator small molecules
MechanismSmall molecule modulators of RNA splicing (SkySTAR platform)